A citation-based method for searching scientific literature

Celia P Kaplan, Jennifer Livaudais-Toman, Jeffrey A Tice, Karla Kerlikowske, Steven E Gregorich, Eliseo J Pérez-Stable, Rena J Pasick, Alice Chen, Jessica Quinn, Leah S Karliner. Cancer Epidemiol Biomarkers Prev 2014
Times Cited: 22







List of co-cited articles
131 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers.
Susan A Sabatino, Ellen P McCarthy, Russell S Phillips, Risa B Burns. Cancer Detect Prev 2007
71
27

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
M H Gail, L A Brinton, D P Byar, D K Corle, S B Green, C Schairer, J J Mulvihill. J Natl Cancer Inst 1989
27

A breast cancer prediction model incorporating familial and personal risk factors.
Jonathan Tyrer, Stephen W Duffy, Jack Cuzick. Stat Med 2004
648
22


Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
Angela Fagerlin, Amanda J Dillard, Dylan M Smith, Brian J Zikmund-Fisher, Rosemarie Pitsch, Jennifer B McClure, Sarah Greene, Sharon Hensley Alford, Vijayan Nair, Daniel F Hayes,[...]. Breast Cancer Res Treat 2011
56
22

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. JAMA 2006
22

Implementation in a large health system of a program to identify women at high risk for breast cancer.
William L Owens, Thomas J Gallagher, Michael J Kincheloe, Victoria L Ruetten. J Oncol Pract 2011
28
22

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Jack Cuzick, Ivana Sestak, John F Forbes, Mitch Dowsett, Jill Knox, Simon Cawthorn, Christobel Saunders, Nicola Roche, Robert E Mansel, Gunter von Minckwitz,[...]. Lancet 2014
337
22

Using clinical factors and mammographic breast density to estimate breast cancer risk: development and validation of a new predictive model.
Jeffrey A Tice, Steven R Cummings, Rebecca Smith-Bindman, Laura Ichikawa, William E Barlow, Karla Kerlikowske. Ann Intern Med 2008
330
22

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial.
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. Lancet Oncol 2015
222
18

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Bernard Fisher, Joseph P Costantino, D Lawrence Wickerham, Reena S Cecchini, Walter M Cronin, Andre Robidoux, Therese B Bevers, Maureen T Kavanah, James N Atkins, Richard G Margolese,[...]. J Natl Cancer Inst 2005
829
18

Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older.
Andrew N Freedman, Binbing Yu, Mitchell H Gail, Joseph P Costantino, Barry I Graubard, Victor G Vogel, Garnet L Anderson, Worta McCaskill-Stevens. J Clin Oncol 2011
123
18

Exemestane for breast-cancer prevention in postmenopausal women.
Paul E Goss, James N Ingle, José E Alés-Martínez, Angela M Cheung, Rowan T Chlebowski, Jean Wactawski-Wende, Anne McTiernan, John Robbins, Karen C Johnson, Lisa W Martin,[...]. N Engl J Med 2011
551
18

Factors affecting breast cancer risk reduction practices among California physicians.
Celia Patricia Kaplan, Jennifer S Haas, Eliseo J Pérez-Stable, Genevieve Des Jarlais, Steven E Gregorich. Prev Med 2005
68
18


Validation studies for models projecting the risk of invasive and total breast cancer incidence.
J P Costantino, M H Gail, D Pee, S Anderson, C K Redmond, J Benichou, H S Wieand. J Natl Cancer Inst 1999
488
18

Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population.
Cecelia A Bellcross, Amy A Lemke, Laura S Pape, Angela L Tess, Lorraine T Meisner. Genet Med 2009
66
18


Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
Katrina Armstrong, Ellyn Micco, Amy Carney, Jill Stopfer, Mary Putt. JAMA 2005
281
18


Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis.
S G Smith, I Sestak, A Forster, A Partridge, L Side, M S Wolf, R Horne, J Wardle, J Cuzick. Ann Oncol 2016
125
18

American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography.
Debbie Saslow, Carla Boetes, Wylie Burke, Steven Harms, Martin O Leach, Constance D Lehman, Elizabeth Morris, Etta Pisano, Mitchell Schnall, Stephen Sener,[...]. CA Cancer J Clin 2007
18


Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups.
Celia Patricia Kaplan, Jennifer S Haas, Eliseo J Pérez-Stable, Steven E Gregorich, Carol Somkin, Genevieve Des Jarlais, Karla Kerlikowske. Cancer Epidemiol Biomarkers Prev 2006
59
13

Development and evaluation of a breast cancer prevention decision aid for higher-risk women.
Dawn Stacey, Annette M O'Connor, Cathy DeGrasse, Shailendra Verma. Health Expect 2003
56
13

Diffusion of breast cancer risk assessment in primary care.
Carmen E Guerra, Melani Sherman, Katrina Armstrong. J Am Board Fam Med 2009
32
13

Projecting individualized absolute invasive breast cancer risk in African American women.
Mitchell H Gail, Joseph P Costantino, David Pee, Melissa Bondy, Lisa Newman, Mano Selvan, Garnet L Anderson, Kathleen E Malone, Polly A Marchbanks, Worta McCaskill-Stevens,[...]. J Natl Cancer Inst 2007
185
13

Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors.
Sharon L Bober, Lizbeth A Hoke, Rosemary B Duda, Meredith M Regan, Nadine M Tung. J Clin Oncol 2004
106
13


American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Kala Visvanathan, Rowan T Chlebowski, Patricia Hurley, Nananda F Col, Mary Ropka, Deborah Collyar, Monica Morrow, Carolyn Runowicz, Kathleen I Pritchard, Karen Hagerty,[...]. J Clin Oncol 2009
197
13

"Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital.
Talya Salant, Pamela S Ganschow, Olufunmilayo I Olopade, Diane S Lauderdale. J Gen Intern Med 2006
51
13

Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Stephanie R Land, D Lawrence Wickerham, Joseph P Costantino, Marcie W Ritter, Victor G Vogel, Myoungkeun Lee, Eduardo R Pajon, James L Wade, Shaker Dakhil, James B Lockhart,[...]. JAMA 2006
166
13

Patient reluctance toward tamoxifen use for breast cancer primary prevention.
E R Port, L L Montgomery, A S Heerdt, P I Borgen. Ann Surg Oncol 2001
155
13

Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Joy Melnikow, Debora Paterniti, Rahman Azari, Christina Kuenneth, Stephen Birch, Miriam Kuppermann, James Nuovo, Janet Keyzer, Stuart Henderson. Cancer 2005
60
13

The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation.
Kelly A Metcalfe, Carrie Snyder, Jennifer Seidel, Danielle Hanna, Henry T Lynch, Steven Narod. Fam Cancer 2005
65
13

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Victor G Vogel, Joseph P Costantino, D Lawrence Wickerham, Walter M Cronin, Reena S Cecchini, James N Atkins, Therese B Bevers, Louis Fehrenbacher, Eduardo R Pajon, James L Wade,[...]. Cancer Prev Res (Phila) 2010
386
13

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Umberto Veronesi, Patrick Maisonneuve, Nicole Rotmensz, Bernardo Bonanni, Peter Boyle, Giuseppe Viale, Alberto Costa, Virgilio Sacchini, Roberto Travaglini, Giuseppe D'Aiuto,[...]. J Natl Cancer Inst 2007
147
13

Use of the Gail model and breast cancer preventive therapy among three primary care specialties.
Jennifer Corbelli, Sonya Borrero, Rachel Bonnema, Megan McNamara, Kevin Kraemer, Doris Rubio, Irina Karpov, Melissa McNeil. J Womens Health (Larchmt) 2014
30
13

Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.
Douglas E Levy, Stacey D Byfield, Catherine B Comstock, Judy E Garber, Sapna Syngal, William H Crown, Alexandra E Shields. Genet Med 2011
152
13


Implementing family health history risk stratification in primary care: impact of guideline criteria on populations and resource demand.
Lori A Orlando, R Ryanne Wu, Chris Beadles, Tiffany Himmel, Adam H Buchanan, Karen P Powell, Elizabeth R Hauser, Vincent C Henrich, Geoffrey S Ginsburg. Am J Med Genet C Semin Med Genet 2014
27
13


Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
Kala Visvanathan, Patricia Hurley, Elissa Bantug, Powel Brown, Nananda F Col, Jack Cuzick, Nancy E Davidson, Andrea Decensi, Carol Fabian, Leslie Ford,[...]. J Clin Oncol 2013
198
13

Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.
Ida J Korfage, Andrea Fuhrel-Forbis, Peter A Ubel, Brian J Zikmund-Fisher, Sarah M Greene, Jennifer B McClure, Dylan M Smith, Sharon Hensley Alford, Angela Fagerlin. Breast Cancer Res 2013
26
13

Mammographic density and the risk and detection of breast cancer.
Norman F Boyd, Helen Guo, Lisa J Martin, Limei Sun, Jennifer Stone, Eve Fishell, Roberta A Jong, Greg Hislop, Anna Chiarelli, Salomon Minkin,[...]. N Engl J Med 2007
9

Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
S A Narod, J S Brunet, P Ghadirian, M Robson, K Heimdal, S L Neuhausen, D Stoppa-Lyonnet, C Lerman, B Pasini, P de los Rios,[...]. Lancet 2000
383
9

Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.
Judy C Boughey, Lynn C Hartmann, Stephanie S Anderson, Amy C Degnim, Robert A Vierkant, Carol A Reynolds, Marlene H Frost, V Shane Pankratz. J Clin Oncol 2010
70
9

Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer.
Fritcher Emily G Barr, Amy C Degnim, Lynn C Hartmann, Derek C Radisky, Judy C Boughey, Stephanie S Anderson, Robert A Vierkant, Marlene H Frost, Daniel W Visscher, Carol Reynolds. Cancer Prev Res (Phila) 2011
17
11

Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women.
Erika A Waters, Kathleen A Cronin, Barry I Graubard, Paul K Han, Andrew N Freedman. Cancer Epidemiol Biomarkers Prev 2010
109
9

The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S R Cummings, S Eckert, K A Krueger, D Grady, T J Powles, J A Cauley, L Norton, T Nickelsen, N H Bjarnason, M Morrow,[...]. JAMA 1999
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.